Quanta Therapeutics Announces Two Late-Breaking Preclinical Presentations from KRAS Inhibitor Pipeline at Annual AACR Meeting
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancers, today announced the acceptance of two late-breaking abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-19, 2023, in Orlando, Florida. Leveraging a differentiated mechanism of action that targets multiple conformations of KRAS, Quanta Therapeutics' allosteric approach has the potential to target the majority of KRAS mutations while evading known mechanisms of resistance.
AACR presentation information:
Title: Discovery and characterization of QTX3034, a potent, selective, and orally bioavailable allosteric KRAS inhibitor
Title: Discovery and characterization of QTX3046, a potent, selective, and orally bioavailable non-covalent KRASG12D inhibitor
About Quanta Therapeutics
Find more information at https://www.quantatx.com/
Follow us on LinkedIn: Quanta Therapeutics